Drug delivery related to metabolites in human breath – first results of long term clinical studies using MCC/IMS

M. Westhoff1, P. Litterst1, S. Maddula2, J.I. Baumbach2,3

1 Lung Clinic Hemer, Theo-Funcke-Str. 1, 58675 Hemer, Germany
2 KIST Europe, Department Microfluidics and Clinical Diagnostics, Campus E 72, 44123 Münster, Germany
3 B&S Analytik, BioMedicalCenter Dortmund, Otto-Hahn-Str. 15, 44227 Dortmund, Germany

Hunter disease is a mucopolysaccharidosis for which enzyme replacement therapy with idursulfase has been offered for 3 years. Therapy can be monitored by the urinary concentration of dermatan sulfate and heparin sulfate. A 38-year-old male person suffering from Hunter disease has been treated with idursulfase for a year, showing dramatic clinical improvement. Additionally, the patient had breath analysis using MCC/IMS every week before enzyme replacement. The patient showed increasing concentrations of a peak P-1.5/0.547 which is related to acetone [67-64-1] over the time.

The concentrations were higher than the concentrations of all patients ever tested with MCC/IMS. Furthermore, a peak P-77.2/0.601 was found, which decreased after few weeks of therapy and needs further biochemical characterisation. Parallel GC/MSD investigations suggest (S)-(+) -6-Methyl-1-octanol[110453-78-6], Cyclohexanone, 5-methyl-2-(1-methylhexyl) -[10458-14-7], Benzaldehyde, 2,5-dimethyl-[5779-94-2], Ethane, 1-(4-methylphenyl)- [122-00-9], Dodecane [112-40-3] or Decanal [112-31-2].

These preliminary data show that breath analysis in patients with metabolic disorders might give further information about metabolism, especially under enzyme replacement therapy.